BioSpace News Archive

Centene Corporation announced the appointment of Jennifer Gilligan to Senior Vice President, Investor Relations.

ChromaDex Corp. announced the expansion of its industry-leading reference standards business with a new line of cannabinoid reference standards available to researchers across the globe.

Alpha Pro Tech, Ltd. (NYSE American: APT), today announced that the company is exponentially ramping up production of its N-95 Particulate Respirator face mask in response to a significant increase in customer demand and level of orders resulting from the outbreak of the novel Wuhan coronavirus

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced the appointment of Michelle Senchyna, Ph.D., as Vice President,

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today that it submitted a New Drug Application prior-approval efficacy supplement for BIJUVA 0.5 mg/100 mg (estradiol and progesterone) capsules to the U.S. Food and Drug Administration (FDA) late January 2020.

Terrace Global Inc. (“Terrace Global” or the “Company”) (TSXV:TRCE) is pleased to announce that effective immediately, Stephen Lermer has joined the Company as President and Chief Operating Officer.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that it has successfully achieved its patient screening target in its 14-week pivotal CONNECT-FX (Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X) trial assessing the efficacy and safety of Zygel™ CBD Gel

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report fourth quarter and full-year 2019 financial results on Monday, February 24, 2020 after the market closes